Log In
Print this Print this

Pan-influenza A mAb (MEDI8852)

  Manage Alerts
Collapse Summary General Information
Company Humabs BioMed S.A.
DescriptionIgG1 kappa mAb that binds the hemagglutinin stem region shared by all 18 influenza A virus subtypes
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationInfluenza virus
Indication DetailsTreat influenza A virus infection
Regulatory Designation U.S. - Fast Track (Treat influenza A virus infection)
PartnerAstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today